Table 2.
Independent associations of serum lipid levels with risk of NSCLC metastasis
| Subgroup | Full population | Propensity score-matched population | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Case (138) | Control (386) | OR (95%CI)* | PVALUE | Case (110) | Control (110) | OR (95%CI) | PVALUE | |||
| TC | 0.002 | 0.110 | ||||||||
| Q1 | 8 (5.80) | 49 (12.70) |  |
1.00 (ref) | 5 (4.50) | 12 (10.9) |  |
1.00 (ref) | ||
| Q2 | 9 (6.50) | 46 (11.90) | 1.13 (0.38-3.38) | 0.825 | 8 (7.30) | 12 (10.9) | 1.52 (0.37-6.29) | 0.560 | ||
| Q3 | 12 (8.70) | 47 (12.20) | 1.12 (0.39-3.17) | 0.838 | 8 (7.30) | 13 (11.8) | 1.59 (0.36-7.01) | 0.540 | ||
| Q4 | 109 (79) | 244 (63.20) | 3.07 (1.32-7.10) | 0.009 | 89 (80.90) | 73 (66.4) | 3.05 (0.95-9.78) | 0.060 | ||
| continues | 6.12 (1.03) | 5.72 (1.270) | 1.44 (1.17-1.77) | 0.001 | 6.16 (1.01) | 5.82 (1.27) | 1.35 (1.03-1.74) | 0.025 | ||
| TG | 0.337 | 0.690 | ||||||||
| Q1 | 12 (8.70) | 46 (11.90) | 1.00 (ref) | 8 (7.30) | 12 (10.90) | 1.00 (ref) | ||||
| Q2 | 26 (18.80) | 88 (22.80) | 1.11 (0.48-2.55) | 0.808 | 21 (19.10) | 22 (20.00) | 1.39 (0.47-4.12) | 0.560 | ||
| Q3 | 77 (55.80) | 209 (54.10) | 1.45 (0.67-3.13) | 0.344 | 62 (56.40) | 61 (55.50) | 1.51 (0.60-3.80) | 0.380 | ||
| Q4 | 23 (16.70) | 43 (11.10) | 1.99 (0.81-4.88) | 0.133 | 19 (17.30) | 15 (13.60) | 2.09 (0.62-7.01) | 0.230 | ||
| continues | 1.51 (0.66) | 1.46 (0.89) | 1.08 (0.86-1.36) | 0.507 | 1.55 (0.71) | 1.50 (0.86) | 1.09 (0.76-1.56) | 0.650 | ||
| HDL-C | 0.029 | 0.330 | ||||||||
| Q1 | 5 (3.60) | 51 (13.20) | 1.00 (ref) | 5 (4.50) | 12 (10.90) | 1.00 (ref) | ||||
| Q2 | 14 (10.10) | 45 (11.70) | 2.44 (0.78-7.66) | 0.125 | 9 (8.20) | 8 (7.30) | 3.03 (0.68-13.46) | 0.150 | ||
| Q3 | 15 (10.90) | 45 (11.70) | 2.18 (0.70-6.79) | 0.179 | 12 (10.90) | 14 (12.70) | 2.23 (0.60-8.26) | 0.230 | ||
| Q4 | 104 (75.40) | 245 (63.50) | 3.82 (1.42-10.27) | 0.008 | 84 (76.40) | 76 (69.10) | 2.91 (0.91-9.27) | 0.070 | ||
| continues | 1.50 (0.25) | 1.41 (0.33) | 2.85 (1.34-6.07) | 0.007 | 1.50 (0.25) | 1.44 (0.30) | 2.45 (0.86-7.03) | 0.095 | ||
| LDL-C | 0.008 | 0.040 | ||||||||
| Q1 | 10 (7.20) | 46 (11.90) | 1.00 (ref) | 7 (6.40) | 14 (12.70) | 1.00 (ref) | ||||
| Q2 | 9 (6.50) | 47 (12.20) | 0.93 (0.33-2.60) | 0.885 | 8 (7.30) | 11 (10.00) | 1.39 (0.37-5.18) | 0.630 | ||
| Q3 | 49 (35.50) | 160 (41.50) | 1.37 (0.61-3.08) | 0.440 | 38 (34.50) | 47 (42.70) | 1.67 (0.61-4.63) | 0.320 | ||
| Q4 | 70 (50.70) | 133 (34.50) | 2.50 (1.13-5.53) | 0.023 | 57 (51.80) | 38 (34.50) | 3.92 (1.31-11.77) | 0.020 | ||
| continues | 2.26 (0.14) | 2.43 (2.28) | 0.89 (0.63-1.25) | 0.493 | 2.27 (0.14) | 2.24 (0.20) | 2.11 (0.47-9.46) | 0.330 | ||
*Univariate Logistic Regression Mode, OR were evaluated by adjusting: age, sex, receiving radiotherapy or chemotherapy, smoking status, alcohol status, previous disease history, family history of cancer, cancer topography, cancer grade, and cancer type.